Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × abemaciclib × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Neoplasm Metastasis 4 Prostatic Neoplasms 3 Glioma 3 Brain Neoplasms 3 Sarcoma, Ewing 2 Recurrence 2 Neoplasms 2 Meningioma 2 Glioblastoma 2 Endometrial Neoplasms 2 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasm, Residual 1 Multiple Myeloma 1 Medulloblastoma 1 Malignant Neoplasms of Female Genital Organs 1 Lymphoma, Non-Hodgkin 1 Liver Metastases From Colorectal Cancer (mCRC) 1 Liposarcoma 1 Leiomyosarcoma 1 Hemangiosarcoma 1

Interventions

pembrolizumab 2 fludarabine 2 blinatumomab 2 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 relugolix 1 nilotinib 1 isatuximab 1 inavolisib 1 giredestrant 1 fludarabine phosphate 1 enzalutamide 1 abemaciclib 1 Transplantation 1 Monatide (IMS 3015) 1 Melphalan 1 Lenalidomide 1 Immunotherapy 1 Imatinib Mesylate 1 HMPL-013 1 Docetaxel 1 Dexamethasone 1 Dasatinib 1 Cyclophosphamide 1 Capecitabine 1 Calcium Dobesilate 1 Biological Assay 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05708235 2026-03-05

MiRaDoR

MedSIR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡